| Literature DB >> 24152990 |
Danica Baines1, Mark Sumarah, Gretchen Kuldau, Jean Juba, Alberto Mazza, Luke Masson.
Abstract
Mycotoxin mixtures are associated with Shiga toxin-producing Escherichia coli (STEC) infections in mature cattle. STEC are considered commensal bacteria in mature cattle suggesting that mycotoxins provide a mechanism that converts this bacterium to an opportunistic pathogen. In this study, we assessed the mycotoxin content of hemorrhaged mucosa in dairy calves during natural disease outbreaks, compared the virulence genes of the STECs, evaluated the effect of the mucosal mycotoxins on STEC toxin expression and evaluated a Celmanax®/Dairyman's Choice™ application to alleviate disease. As for human infections, the OI-122 encoded nleB gene was common to STEC genotypes eliciting serious disease. Low levels of aflatoxin (1-3 ppb) and fumonisin (50-350 ppb) were detected in the hemorrhaged mucosa. Growth of the STECs with the mycotoxins altered the secreted protein concentration with a corresponding increase in cytotoxicity. Changes in intracellular calcium indicated that the mycotoxins increased enterotoxin and pore-forming toxin activity. A prebiotic/probiotic application eliminated the morbidity and mortality losses associated with the STEC infections. Our study demonstrates: the same STEC disease complex exists for immature and mature cattle; the significance of the OI-122 pathogenicity island to virulence; the significance of mycotoxins to STEC toxin activity; and, finally, provides further evidence that prebiotic/probiotic applications alleviate STEC shedding and mycotoxin/STEC interactions that lead to disease.Entities:
Mesh:
Substances:
Year: 2013 PMID: 24152990 PMCID: PMC3813917 DOI: 10.3390/toxins5101872
Source DB: PubMed Journal: Toxins (Basel) ISSN: 2072-6651 Impact factor: 4.546
Clinical symptoms recorded for STEC-associated hemorrhagic enteritis (HE) cases in dairy calves from three production sites (A,B,C), jejunal hemorrhage syndrome (JHS) cases in older calves and mature cattle (D) and beef feeder calves from experimental O157 STEC challenge studies (E).
| Site–Disease, serotype | Scour | Respiration | Appearance | Death |
|---|---|---|---|---|
| A–HE, O145 > ExPEC a | after death: watery to white scour with no fecal matter and the presence of mucus and blood | normal | normal | mortality without warning |
| A–HE, O145 < ExPEC | dark brown feces with the presence of mucus and blood | normal changing to labored | depressed with drooping head, wasting, progressing to flat on its side | progressive |
| B–HE, O177 | dark brown feces with the presence of mucus and blood | normal changing to labored | depressed with drooping head, wasting, progressing to flat on its side | progressive |
| C–HE, O174/O177 | dark brown feces with the presence of mucus and blood | normal changing to labored | depressed with drooping head, wasting, progressing to flat on its side | progressive |
| D–JHS, (O157, O145, O177,O174, ExPEC) | grey-green feces | normal changing to labored | diarrhea, recumbent, wasting, hind end paralysis | progressive |
| E–HE, O157 (E318N, E32511N, H4420N, R508N) | runny feces | normal | normal | persistent shedding |
a Shiga toxin-producing Escherichia coli that cause disease outside the host intestinal tract.
Figure 1Effect of Celmanax®/Dairyman’s Choice™ applications on STEC shedding in calves from three production sites (A,B,C) at day 0 and day 7–14 (n = 3; *** p = 0.001).
Percent of calf feed ration collected from separate bags positive for mycotoxigenic fungi from three dairy production sites (A, B, C; n = 3).
| Mycotoxigenic Fungi | A | B | C |
|---|---|---|---|
|
| 100 | 100 | 100 |
|
| 100 | 100 | 100 |
|
| 100 | 0 | 0 |
|
| 100 | 100 | 100 |
|
| 100 | 100 | 100 |
|
| 100 | 100 | 0 |
Figure 2Impact of Celmanax® and Dairyman’s Choice™ on the cytotoxicity of mycotoxin extracts from calf feed rations (n = 3; 0, extract alone; C, extract + 0.1% Celmanax®; DC, extract + 0.1% Dairyman’s Choice™ calf starter; *** p = 0.001).
Average concentration (ppb) of fumonisin and aflatoxin measured in the hemorrhaged jejunal mucosa of dairy calves using an ELISA-based method.
| Dairy production site | Average Mycotoxin content (Mean ± SE) | |
|---|---|---|
| Aflatoxin (ppb) | Fumonisin (ppb) | |
| A ( | 3 ± 0 | 50 ± 0 |
| B ( | 1 ± 0 | 350 ± 0 |
| C ( | 2 ± 0 | 250 ± 0 |
| Control ( | 0 ± 0 | 0 ± 0 |
Figure 3Effect of STEC-secreted protein composition on intracellular Ca2+ concentrations (340/380 fluorescence) in bovine liver cells. Ca2+ signaling in response to STEC-secreted proteins produced in M9 medium with normal 1 mM extracellular Ca2+ in the medium. The cells were loaded with fura-2/AM and stored in balanced salt solutions with or without Ca2+ to achieve a baseline before addition of the secreted proteins. Each value represents the Ca2+ mobilization for the protein composition secreted by STEC grown in M9 medium evoked in about 10 cells. Data are presented for each STEC involved in the infections at production site A (A1 = O145 STEC, A2 = ExPEC), B (B1–B3 = O177 STEC) and C (C1 = O177 STEC, C2 = O174 STEC). Recordings were performed at 37 °C and the experiment was repeated twice.
Figure 4Effect of STEC-secreted protein composition on intracellular Ca2+ concentrations (340/380 fluorescence) in bovine liver cells. Ca2+ signaling in response to STEC-secreted proteins produced in the absence or presence of aflatoxin (0.02 ppb) or fumonisin (700 ppb) with normal 1 mM extracellular Ca2+ in the medium. The cells were loaded with fura-2/AM and stored in balanced salt solutions with or without Ca2+ to achieve a baseline before addition of the secreted proteins. Each value represents the difference in calcium mobilization of the mycotoxin-treated and untreated STEC-secreted protein composition evoked intracellular Ca2+ concentrations in about 10 cells. Data are presented for each STEC involved in the infections at production site A (A1 = O145 STEC, A2 = ExPEC), B (B1–B3 = O177 STEC) and C (C1 = O177 STEC, C2 = O174 STEC). Recordings were performed at 37 °C and the experiment was repeated twice.
The average production of secreted cytotoxins or proteins (ng/μL) by STECs and their associated threshold dose (ng) for cytotoxicity in a lawn assay using bovine colonic cells. Data are presented for STECs grown in the absence or presence of 0.02 ppb aflatoxin (n = 3).
| STEC | Secreted proteins (ng/µL) | Average Threshold Dose (ng) a |
|---|---|---|
| O145 | 15.34 | 11.1 ± 0a |
| O145 + aflatoxin | 16.59 | 7.3 ± 1.9b |
| ExPEC | 17.97 | 20.0 ± 4a |
| ExPEC+ aflatoxin | 49.83 | 2.5 ± 0.5b |
| O177a | 5.12 | 15.3 ± 0a |
| O177a + aflatoxin | 5.44 | 8.1 ± 0b |
| O177b | 17.05 | 25.5 ± 0a |
| O177b + aflatoxin | 35.20 | 8.4 ± 2.1b |
| O177c | 4.26 | 12.7 ± 0a |
| O177c + aflatoxin | 5.68 | 7.1 ± 1.4b |
| O177 | 157.59 | 8.5 ± 3.2a |
| O177 + aflatoxin | 130.08 | 6.0 ± 1.2b |
| O174 | 16.59 | 20.0 ± 4.0a |
| O174 + aflatoxin | 11.72 | 7.1 ± 1.4b |
a column numbers followed by different letters are significantly different, p = 0.001.
Effect of virulent STEC and avirulent STEC (E318N) toxin mixtures on cell blebbing and monolayer viability. Modulation of cell death pathways for virulent STEC and avirulent O157 STEC (E318N) using a bovine colonic cell line (n = 3).
| STEC | Cell Blebbing | Loss of Monolayer Integrity |
|---|---|---|
| E318N | 3 | |
| O145 | 3 | |
| ExPEC | 3 | |
| O177a | 3 | |
| O177b | 3 | |
| O177c | 3 | |
| O177 | 3 | |
| O174 | 3 |
Adherence pattern for virulent STEC from production sites (A, B, C) and avirulent O157 STEC (E318N) using a bovine colonic cell line (n = 3).
| STEC | Diffuse | Aggregative | Localized |
|---|---|---|---|
| E318N | 3 | ||
| O145 | 3 | ||
| ExPEC | 3 | ||
| O177a | 3 | ||
| O177b | 3 | ||
| O177c | 3 | ||
| O177 | 3 | ||
| O174 | 3 |
Comparison of virulence genes from STECs associated with mild to serious disease in immature and mature cattle.
| Genetic Element a | Clinical Symptoms | |||||
|---|---|---|---|---|---|---|
| Virulence Gene b | A ( | B ( | C ( | JHS cases ( | O157 Challenges ( | |
| pMAR2 |
| - | - | - | - | 3 |
| pO157 |
| - | 4 | 2 | 3 | 4 |
| pO157 |
| 2 | - | - | - | 4 |
| pO157 |
| - | - | 2 | 2 | 4 |
| pO157 |
| 2 | - | - | - | 4 |
| OI-71 |
| - | 4 | 2 | 2 | 4 |
| OI-71 |
| 2 | 4 | 2 | - | - |
| OI-71 |
| - | - | 2 | 2 | - |
| OI-71 |
| 2 | nd c | nd | nd | nd |
| OI-122 |
| 2 | 4 | - | 2 | - |
| OI-122 |
| 2 | 4 | 2 | - | - |
| OI-122 |
| - | 4 | 2 | 2 | - |
| OI-57 |
| - | - | - | - | - |
| OI-57 |
| 2 | - | 2 | - | - |
| OI-36 |
| 2 | nd | nd | nd | nd |
| Stx-phage |
| 2 | 4 | 2 | 3 | 2 |
| Stx-phage |
| 2 | - | - | - | 4 |
| LEE |
| 2 | 4 | 2 | 5 | 4 |
a pMAR2, Enteropathogenic E. coli (EPEC) adherence factor plasmid; pO157, O157 Enterohemorrhagic E. coli (EHEC) virulence plasmid; OI, O islands are unique DNA segments present in virulent E. coli. There are 177 O islands; OI-71, O island number 71; OI-122, O island number 122; OI-57, O island number 57; OI-36, O island number 36; Stx-phage, prophage encoded stx genes; LEE, Locus of Enterocyte Effacement Genes; b bfpA, bundle forming pili A; ehxA, hemolysin; espP, extracellular serine protease; etpD, type II secretion system; katP, catalase/peroxidase; nleA (EHEC) or nle (EPEC), an EHEC/EPEC translocated effector endoplasmic reticulum protein export inhibitor; nleF, apoptosis inhibitor; nleH, apoptosis inhibitor; nleB(O103) or nleB (O157) suppresses NF-κB activation; nleE, inhibits p65 nuclear translocation; nleG (O103) or nleG (O157), E3 ubiquitin ligases; nleD, prevents JNK-mediated pro-apoptotic signaling by cleaving and inactivating JNK; stx1, Shiga toxin 1; stx2, Shiga toxin 2; eae, intimin; c nd, no data.
Antibiotic resistance associated gene profiles for STECs causing mild to serious symptoms in calves less than one month old.
| Oligonucleotide Primer a | A O145 | A ExPEC | B O177a | B O177b | B O177c | B O177d | C O174 | C O177 |
|---|---|---|---|---|---|---|---|---|
|
| 0 | 1 | 1 | 1 | 1 | 1 | 0 | 0 |
|
| 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
|
| 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
|
| 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
|
| 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 |
|
| 0 | 0 | 1 | 1 | 0 | 1 | 0 | 0 |
|
| 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 |
|
| 0 | 0 | 1 | 1 | 1 | 1 | 0 | 0 |
|
| 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
|
| 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
|
| 0 | 1 | 1 | 1 | 1 | 1 | 0 | 0 |
|
| 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 |
|
| 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
|
| 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
|
| 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
|
| 0 | 0 | 1 | 1 | 1 | 1 | 0 | 0 |
|
| 0 | 0 | 1 | 1 | 1 | 1 | 0 | 0 |
|
| 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
|
| 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
|
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
|
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
a Resistance genes. 70-aadA(1)290, streptomycin; 70-aacC(2)200, gentamicin; 70-aphA(1)1310, Kanamycin; 70-cat(3)370, Chloramphenicol; 70-dhfr(5)1560, Trimethoprim; 70-dhfr(7)753, Trimethoprim; 70-dhfr(9)830, Trimethoprim; 70-oxa(7)295, β-lactamase; 70-sul(2)420, Sulfonamide; 70-tem8674, β-lactamase; 70-tetB190, Tetracycline; F_aph3strA, Kanamycin; F_aph6, Kanamycin; F_bla_SME1, carbapenemases; F_bla_VIM2, carbapenemases; F_cat, Chloramphenicol; F_ereB, susceptibility to mercury compounds; F_tnpM, integrons associated with novel combinations of resistance genes; RB_ereA2, probe for macrolide resistance; F_mphA, probe for macrolide resistance; RB_dhfrXII, Trimethoprim.
Toxin gene profiles for STECs causing HE cases in calves less than one month old.
| Oligonucleotide Primer a | A O145 | A ExPEC | B O177a | B O177b | B O177c | C O174 | C O177 |
|---|---|---|---|---|---|---|---|
|
| 0 | 1 | 0 | 1 | 1 | 1 | 1 |
|
| 0 | 1 | 1 | 1 | 1 | 1 | 1 |
|
| 0 | 0 | 0 | 1 | 1 | 0 | 0 |
|
| 0 | 0 | 1 | 0 | 1 | 0 | 0 |
|
| 0 | 0 | 1 | 1 | 1 | 1 | 1 |
|
| 0 | 0 | 1 | 1 | 1 | 1 | 1 |
|
| 0 | 1 | 0 | 0 | 0 | 0 | 0 |
|
| 0 | 1 | 0 | 0 | 0 | 0 | 0 |
|
| 1 | 0 | 0 | 0 | 0 | 0 | 0 |
a Toxin genes. 70-astA(2)183, Enteroaggregative E. coli heat-stable enterotoxin 1; 70-astA130, Enteroaggregative E. coli heat-stable enterotoxin 1; 70-esta1365, heat-stable enterotoxin I; 70-hlyE867, silent hemolysin (haemolytic phenotype when overexpressed); 70-stx1A742, Shiga toxin 1A; 70-stx1B1454, Shiga toxin 1B, 70-stx2A1087, Shiga toxin 2A; 70-stx2B(1)1353503, Shiga toxin 2B; 70-rtx586651, putative RTX family exoprotein.